
-
PTC Therapeutics NasdaqGS:PTCT PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.
Location: 500 Warren Corporate Center Drive, Warren, NJ, 07059, United States | Website: https://www.ptcbio.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
4.325B
Cash
2.038B
Avg Qtr Burn
N/A
Short % of Float
8.02%
Insider Ownership
2.42%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
KEBILIDI™ (eladocagene exuparvovec) Details Aromatic L-amino acid decarboxylase deficiency | Approved Quarterly sales | |
Evrysdi (riskiplam) Details Spinal muscular atrophy | Approved Quarterly sales | |
Emflaza (deflazacort) Details Duchenne muscular dystrophy | Approved Quarterly sales | |
Translarna (ataluren) Details Duchenne muscular dystrophy | PDUFA Approval decision | |
Vatiquinone (PTC743) Details Friedreich’s Ataxia | PDUFA Approval decision | |
Sepiapterin (PTC923) Details Phenylketonuria | PDUFA Approval decision | |
PTC518 Details Huntington's disease | Phase 2 Update | |
Vatiquinone (PTC743) Details Epilepsy, Mitochondrial disease | Failed Discontinued | |
Utreloxastat Details Amyotrophic lateral sclerosis | Failed Discontinued | |
PTC299 (DHODH inhibitor) Details COVID-19 | Failed Discontinued |